Collectively, these 8 trials support the use of anti-PD-1/PD-L1 therapy in conjunction with chemotherapy as a new standard first-line systemic therapy for advanced ESCC [14–26]. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.